Eye injection could stop damaging blood vessels in Herpes-Related blindness

NCT ID NCT07329686

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting anti-VEGF medication directly into the cornea can safely reduce abnormal blood vessel growth caused by herpes simplex keratitis. One hundred adults will receive either the injection plus antiviral eye drops or standard antiviral drops alone. Researchers will measure changes in blood vessel area, vision, and eye clarity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-VEGF medication
What this could lead to: If successful, this could offer a new, targeted treatment to reduce abnormal blood vessels in the cornea and improve vision for people with herpes-related eye disease.
What could go wrong: This is an early Phase 1/2 trial with only 100 participants, so results are preliminary. The injection procedure itself carries risks like infection or corneal damage, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates